Long-term efficacy of etanercept for psoriasis in daily practice

被引：15
作者：
van Lumig, P. P. M. [1 ]
Driessen, R. J. B. [1 ]
Boezeman, J. B. M. [1 ]
van de Kerkhof, P. C. M. [1 ]
de Jong, E. M. G. J. [1 ]
机构：
[1] Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, NL-6525 GL Nijmegen, Netherlands
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2012年 / 166卷 / 02期
关键词：
SAFETY; MONOTHERAPY; EXPERIENCE; THERAPIES; TRIAL;
D O I：
10.1111/j.1365-2133.2011.10584.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：445 / 447
页数：3
相关论文
共 10 条
[1]   Tolerability and Safety of Biological Therapies for Psoriasis in Daily Clinical Practice: A Study of 103 Italian Patients [J].
Brunasso, Alexandra Maria Giovanna ;
Puntoni, Matteo ;
Salvini, Camilla ;
Delfino, Chiara ;
Curcic, Pero ;
Gulia, Andrea ;
Massone, Cesare .
ACTA DERMATO-VENEREOLOGICA, 2011, 91 (01) :44-49
[2]   Initial experience with routine administration of etanercept in psoriasis [J].
de Groot, M. ;
Appelman, M. ;
Spuls, P. I. ;
de Rie, M. A. ;
Bos, J. D. .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (04) :808-814
[3]   Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome [J].
Driessen, R. J. B. ;
Berends, M. A. M. ;
Boezeman, J. B. ;
Van de Kerkhof, P. C. M. ;
de Jong, M. G. J. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (05) :1098-1106
[4]   Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome [J].
Driessen, R. J. B. ;
Boezeman, J. B. ;
van de Kerkhof, P. C. M. ;
de Jong, E. M. G. J. .
BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (03) :670-675
[5]   A randomized trial of etanercept as monotherapy for psoriasis [J].
Gottlieb, AB ;
Matheson, RT ;
Lowe, N ;
Krueger, GG ;
Kang, S ;
Goffe, BS ;
Gaspari, AA ;
Ling, M ;
Weinstein, GD ;
Nayak, A ;
Gordon, KB ;
Zitnik, R .
ARCHIVES OF DERMATOLOGY, 2003, 139 (12) :1627-1632
[6]   Etanercept as monotherapy in patients with psoriasis [J].
Leonardi, CL ;
Powers, JL ;
Matheson, RT ;
Goffe, BS ;
Zitnik, R ;
Wang, A ;
Gottlieb, AB ;
Bagel, J ;
Camisa, C ;
Caro, I ;
DiGiovanna, JJ ;
Dunlap, FF ;
Elewski, BE ;
Gribetz, CE ;
Farber, HF ;
Feldman, SR ;
Frankel, EH ;
Gaspari, AA ;
Goodman, JJ ;
Gordon, KB ;
Hampel, FC ;
Herdener, RS ;
Hoffman, MD ;
Humeniuk, JM ;
Johnson, SM ;
Kang, S ;
Kimball, AB ;
Kirsner, RS ;
Korman, NJ ;
Krueger, GG ;
Kuwahara, RT ;
Lebwohl, M ;
Ling, MR ;
Liu, DC ;
Lowe, N ;
McCall, CO ;
Menter, A ;
Miller, BH ;
Moore, JK ;
Nayak, AS ;
Ratner, PH ;
Savin, RC ;
Shupack, JL ;
Smith, SL ;
Stone, SP ;
Swinehart, JM ;
Taborn, J ;
Tschen, EH ;
Weinstein, GD ;
Werth, VP .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2014-2022
[7]   The Impact of Methodological Approaches for Presenting Long-Term Clinical Data on Estimates of Efficacy in Psoriasis Illustrated by Three-Year Treatment Data on Infliximab [J].
Papoutsaki, M. ;
Talamonti, M. ;
Giunta, A. ;
Costanzo, A. ;
Ruzzetti, M. ;
Teoli, M. ;
Chimenti, S. .
DERMATOLOGY, 2010, 221 :43-47
[8]   A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction [J].
Papp, KA ;
Tyring, S ;
Lahfa, M ;
Prinz, J ;
Griffiths, CEM ;
Nakanishi, AM ;
Zitnik, R ;
van de Kerkhof, PCM .
BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (06) :1304-1312
[9]   Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis [J].
Tyring, Stephen ;
Gordon, Kenneth B. ;
Poulin, Yves ;
Langley, Richard G. ;
Gottlieb, Alice B. ;
Dunn, Meleana ;
Jahreis, Angelika .
ARCHIVES OF DERMATOLOGY, 2007, 143 (06) :719-726
[10]   Biologic therapies for psoriasis: practical experience in a UK tertiary referral centre [J].
Warren, R. B. ;
Brown, B. C. ;
Lavery, D. ;
Ashcroft, D. M. ;
Griffiths, C. E. M. .
BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (01) :162-169
1